Filtered By:
Drug: Fortamet

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 8614 results found since Jan 2013.

Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: Metformin use in pregnancy
ConclusionsMetformin may represent a therapeutic option in selected women with obesity, PCOS, GDM, T2DM, and in women undergoing ART. However, more research is required specifically on the long-term effects of in utero exposition to metformin.
Source: Acta Diabetologica - July 4, 2023 Category: Endocrinology Source Type: research

In search of the mechanisms of metformin in cancer
In search of the mechanisms of metformin in cancer, Published online: 26 September 2018; doi:10.1038/s41574-018-0104-3In search of the mechanisms of metformin in cancer
Source: Nature Reviews Endocrinology - September 26, 2018 Category: Endocrinology Authors: Alan Morris Source Type: research

Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials
Conclusions Metformin may be beneficial in treating gestational diabetes. However, even more studies are needed to provide more evidence for the future use of metformin.
Source: Irish Journal of Medical Science - February 9, 2016 Category: Journals (General) Source Type: research

Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trial.
CONCLUSION: Metformin showed significant improvement in clinical outcomes but not in metabolic and endocrine outcomes in PCOS women; however, heterogeneity between studies was found to be moderate to high. PMID: 28058854 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - January 11, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
This article reviews evidence of benefits and risk of antidiabetic agents in cardiovascular (CV) outcomes, with a focus on medications approved by the FDA since 2008. Peer-reviewed articles were identified from MEDLINE and Current Content database (both 1966 to October 1, 2016) using the search terms insulin, metformin, rosiglitazone, pioglitazone, glyburide, glipizide, glimepiride, acarbose, miglitol, albiglutide, exenatide, liraglutide, lixisenatide, dulaglutide, pramlintide, meglitinide, alogliptin, linagliptin, saxagliptin, sitagliptin, canagliflozin, dapagliflozin, empagliflozin, colesevalam, bromocriptine, mortality,...
Source: Current Medical Research and Opinion - January 19, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS.
CONCLUSIONS: In this review will discuss the role of a number of natural associations between inositol and different substances in the treatment of hyperandrogenic symptoms in PCOS women. PMID: 28724177 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - July 22, 2017 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and “First Do No Harm” Part III
AbstractPurpose of ReviewTo discuss the overall and latest observations of the effect of diet, lifestyle, supplements, preventive vaccinations, and some prescription heart healthy medications for prostate cancer prevention within a 3-part series of publications.Recent FindingsThe concept of maximizing heart health to prevent aggressive prostate cancer continues to be solidified with additional prospective observational and randomized controlled trial data. Heart healthy is prostate healthy, but heart unhealthy is prostate unhealthy.SummaryThe primary goal for medical providers of reducing all-cause and cardiovascular disea...
Source: Current Urology Reports - May 3, 2020 Category: Urology & Nephrology Source Type: research

The addition of metformin to systemic anticancer therapy in advanced or metastatic cancers: a meta-analysis of randomized controlled trials.
In conclusion, this meta-analysis of randomized clinical trials indicates that the addition of metformin to systemic anticancer therapy has no clinical benefits in patients with advanced or metastatic cancer. PMID: 33029097 [PubMed - in process]
Source: International Journal of Medical Sciences - October 9, 2020 Category: Biomedical Science Tags: Int J Med Sci Source Type: research

The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis
CONCLUSIONS: Due to the dearth of related research and the high heterogeneity of the Randomized Clinical Trials (RCTs) included in other studies, the present systematic review could not establish any differences between metformin and myo-inositol concerning the hormonal profile and the ovarian function. However, the findings indicated that myo-inositol could improve fertility outcomes by modulating hyperandrogenism. Randomized trials are required to understand the mechanistic actions of myo-inositol in comparison with those of metformin regarding oocyte and embryo quality, fertilization, pregnancy, and live birth rates.PMI...
Source: European Review for Medical and Pharmacological Sciences - April 20, 2021 Category: Drugs & Pharmacology Authors: M Azizi Kutenaei S Hosseini Teshnizi P Ghaemmaghami F Eini N Roozbeh Source Type: research